Protein tyrosine kinase 7 (PTK7), originally known as colon carcinoma kinase (CCK4), is an evolutionary conserved, catalytically defective transmembrane receptor involved in Wnt signalling. PTK7 has been identified as a potential therapeutic target, and a PTK7 antibody drug conjugate (PF-06647020; cofetuzumab pelidotin) has been investigated in phase I clinical trials for triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer. PTK7 protein expression was evaluated in 1136 early-stage invasive breast tumours by immunohistochemistry. In addition,PTK7mRNA expression in the METABRIC (n = 1980) and the TCGA breast cancer cohorts (n = 1082) was evaluated. Associations between PTK7 expression and clinicopathological criteria and patient outcome were determined. No association between PTK7 protein expression and breast cancer-specific survival was observed; however,PTK7mRNA expression in the METABRIC cohort was associated with breast cancer-specific survival (p< 0.001). PTK7 protein and mRNA expression were associated with breast cancer-specific survival of patients with a poor prognostic Nottingham Prognostic Index (NPI) and a moderate prognostic NPI, respectively. Taken together, these data indicate that PTK7 expression is associated with patient outcome in subgroups of breast cancer patients.
蛋白酪氨酸激酶7（PTK7），最初被称为结肠癌激酶（CCK4），是一种进化上保守、催化功能缺陷的跨膜受体，参与Wnt信号通路。PTK7已被确定为潜在的治疗靶点，其抗体药物偶联物（PF-06647020；cofetuzumab pelidotin）已在三阴性乳腺癌、卵巢癌和非小细胞肺癌的I期临床试验中进行研究。本研究通过免疫组织化学方法评估了1136例早期浸润性乳腺癌肿瘤中PTK7蛋白的表达情况。此外，还评估了METABRIC队列（n = 1980）和TCGA乳腺癌队列（n = 1082）中PTK7 mRNA的表达水平。分析了PTK7表达与临床病理学标准及患者预后之间的关联。结果显示，PTK7蛋白表达与乳腺癌特异性生存率无显著关联；然而，在METABRIC队列中，PTK7 mRNA表达与乳腺癌特异性生存率相关（p < 0.001）。PTK7蛋白和mRNA表达分别与预后不良的诺丁汉预后指数（NPI）组和预后中等的NPI组患者的乳腺癌特异性生存率相关。综上所述，这些数据表明PTK7表达与乳腺癌患者亚组的预后相关。
肿瘤(癌症)患者之家